Wealthfront Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wealthfront Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,860	Closed	-$3.22M	–	881
2023 Q3	$3.22M	Sell	27,860 -120	-0.4%	-$12.9K	0.01%	316
2023 Q2	$2.88M	Sell	27,980 -805	-3%	-$84.9K	0.01%	337
2023 Q1	$3.14M	Sell	28,785 -911	-3%	-$101K	0.01%	300
2022 Q4	$3.38M	Buy	+29,696	New	+$2.47M	0.02%	272
2022 Q3	–	Sell	-3,191	Closed	-$255K	–	796
2022 Q2	$255K	Sell	3,191 -5,034	-61%	-$477K	﹤0.01%	718
2022 Q1	$866K	Buy	8,225 +6,030	+275%	+$588K	﹤0.01%	542
2021 Q4	$237K	Sell	2,195 -1,603	-42%	-$175K	﹤0.01%	724
2021 Q3	$416K	Buy	+3,798	New	+$394K	﹤0.01%	584

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wealthfront Advisers's HZNP Position: Q4 2023 in Review

Wealthfront Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 27,860 shares — an estimated $3.22M sold.

Wealthfront Advisers first reported a position in HZNP in Q3 2021 and held it in 8 quarters. The position peaked at $3.38M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Wealthfront Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Wealthfront Advisers sold 27,860 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $3.22M.
Wealthfront Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 8 quarters.
Wealthfront Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.38M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Wealthfront Advisers's 13F filing for Q4 2023, filed 9 Feb 2024.